Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Secondary hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    730 result(s) found for: Secondary hypertension. Displaying page 1 of 37.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-003144-23 Sponsor Protocol Number: PANDA Start Date*: 2014-02-03
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: Pregnancy And chronic hypertension: NifeDipine or labetalol as Antihypertensive treatment
    Medical condition: Chronic hypertension in pregnancy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10036695 Primary hypertension LLT
    16.1 10047065 - Vascular disorders 10039834 Secondary hypertension PT
    16.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004411-22 Sponsor Protocol Number: CSPP100A2365E2 Start Date*: 2012-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, 52 to 104 week extension study to evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years of age treated previously with aliskiren
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10047065 - Vascular disorders 10039834 Secondary hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001893-24 Sponsor Protocol Number: Bay63-2521/14986 Start Date*: 2011-10-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: Relative bioavailability and food effect study of two oral liquid formulations in comparison to a 1mg tablet of riociguat to characterize its pharmacokinetic properties in healthy male and female a...
    Medical condition: Children with PH due to • Pulmonary arterial hypertension (PAH) • persistent pulmonary hypertension of the newborn (PPHN)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037405 Pulmonary hypertension primary LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10036727 Primary pulmonary hypertension LLT
    14.0 10010331 - Congenital, familial and genetic disorders 10053592 Newborn persistent pulmonary hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004224-37 Sponsor Protocol Number: EREMIT Start Date*: Information not available in EudraCT
    Sponsor Name:Universität Leipzig
    Full Title: Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie
    Medical condition: - steady or progressive pulmonary hypertension accompanied by at least two of the following parameters associated with a poor prognosis: - Cardiac index ≤ 2,1 l/min/m2 - 6 MWD ≤ 380 m - systolic RR...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001001-41 Sponsor Protocol Number: PR002-CLN-pro008 Start Date*: 2008-06-02
    Sponsor Name:Protherics Medicines Development Ltd, a BTG plc company
    Full Title: A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate Hypertension
    Medical condition: Men and women, 35-70 years old with mild to moderate Hypertension as classified by the British Hypertension Society (BHS) Guidelines - BHS-IV based on the following crietia of sitting blood pressur...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    9.1 10020772 Hypertension PT
    9.1 10042957 Systolic hypertension PT
    9.1 10012758 Diastolic hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024448-13 Sponsor Protocol Number: 010884 Start Date*: 2011-02-18
    Sponsor Name:Netherlands Heart Foundation
    Full Title: Effects of low-dose aspirin taken at bedtime on blood pressure of subjects with who use aspirin for prevention of recurrent cardiovascular events: the Aspirin In Reduction of Tension II (ASPIRETENS...
    Medical condition: The medical condition to be investigated is hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005361-19 Sponsor Protocol Number: 123-2006 Start Date*: 2007-03-09
    Sponsor Name:St Georges Hospital
    Full Title: Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment o...
    Medical condition: Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstru...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005082-19 Sponsor Protocol Number: RB23EZ Start Date*: 2006-12-06
    Sponsor Name:Research Innovation Services, University of Nottingham
    Full Title: Effect of an angiotensin receptor antagonist on cerebral blood flow, cerebral perfusion pressure, and systemic and peripheral haemodynamics in patients with recent stroke.
    Medical condition: Patients who have hypertension in the context of recent stroke.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003975-38 Sponsor Protocol Number: TERPAH-001 Start Date*: 2007-11-22
    Sponsor Name:Ergonex Pharma GmbH
    Full Title: Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective P...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000091-25 Sponsor Protocol Number: 2014GU001B Start Date*: 2014-09-01
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost (Ventavis®) in patients with Eisenmenger syndrome
    Medical condition: Pulmonary Arterial Hypertension Eisenmenger syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10037405 Pulmonary hypertension primary LLT
    17.0 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003776-13 Sponsor Protocol Number: ALN-AGT01-003 Start Date*: 2021-12-15
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled b...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005297-36 Sponsor Protocol Number: CSPP100A2413 Start Date*: 2012-02-23
    Sponsor Name:Novartis Farmaceutica SA
    Full Title: An 8-week randomized, open label, multi-center study to study to evaluate the efficacy and safety of oral aliskiren 300 mg once daily under light meal versus fasted condition in patients with hyper...
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-003558-27 Sponsor Protocol Number: ASPIRANT Start Date*: 2007-07-30
    Sponsor Name:Olomouc University Hospital and Palacký University School of Medicine, Internal Medicine Dept. I
    Full Title: Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)
    Medical condition: arterial hypertension resistant to treatment (target blood pressure not reached with a combination of at least three different antihypertensive drugs, one of them being a diuretic)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020783 Hypertension not adequately controlled LLT
    9.1 10020775 Hypertension arterial LLT
    9.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008260-28 Sponsor Protocol Number: TAK-491CLD_308 Start Date*: 2010-02-03
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-D...
    Medical condition: TAK-491CLD is being evaluated to treat essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001675-37 Sponsor Protocol Number: Lis-Safe Start Date*: 2012-07-24
    Sponsor Name:Sinoxa Pharma GmbH
    Full Title: A Prospective, Open-label, Exploratory Study to Investigate the Safety, Efficacy, and Haemodynamics of Lisuride Subcutaneous Infusion as Add-on to Conventional Treatment in Patients with Pulmonary ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002560-41 Sponsor Protocol Number: 0611 Start Date*: 2017-09-21
    Sponsor Name:University of Leicester
    Full Title: A Calcium channel or Angiotensin converting enzyme inhibitor/Angiotensin receptor blocker Regimen to reduce Blood pressure variability in acute ischaemic Stroke (CAARBS): A Feasibility Trial
    Medical condition: Participants in the trial will have had a transient ischaemic attack (TIA) or an acute ischaemic stroke and will also have hypertension. The trial will investigate the possible treatment of blood p...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10060840 Ischaemic cerebral infarction PT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    20.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    20.0 10047065 - Vascular disorders 10020783 Hypertension not adequately controlled LLT
    20.0 10047065 - Vascular disorders 10036695 Primary hypertension LLT
    20.0 10047065 - Vascular disorders 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004846-17 Sponsor Protocol Number: STH 14399 Start Date*: 2007-03-16
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A randomised, placebo controlled trial of the efficacy of the addition of spironolactone to modern antihypertensive treatment regimes in patients with resistant hypertension.
    Medical condition: Resistant hypertension.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003071-37 Sponsor Protocol Number: QGC001/2QG1 Start Date*: 2014-11-14
    Sponsor Name:Quantum Genomics
    Full Title: Multicenter, randomized, double-blind, two-period, placebo controlled, forced-titration proof of concept crossover study to compare QGC001 with placebo in patients with grade I or II essential hype...
    Medical condition: Hyperactivity of the brain renin-angiotensin system participates to the development and maintenance of essential Hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001248-82 Sponsor Protocol Number: ALN-AGT01-002 Start Date*: 2022-10-14
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients with Mild-to-Moderate Hypertension
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002439-33 Sponsor Protocol Number: MeIn/08/ZOF+HCTZ-HYP/001 Start Date*: 2008-06-26
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
    Full Title: EFFICACY AND SAFETY OF ZOFENOPRIL + HYDROCHLOROTHIAZIDE COMBINATION VS IRBESARTAN + HYDROCHLOROTHIAZIDE COMBINATION IN ESSENTIAL HYPERTENSIVE PATIENTS NOT CONTROLLED BY PREVIOUS MONOTHERAPY
    Medical condition: Patients with essential hypertension and with at least one additional cardiovascular risk factor, not controlled by a previous monotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) LT (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 15:31:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA